Can food allergy be cured?
DOI:
https://doi.org/10.6092/1828-6550/APMB.107.2.2019.SD1Keywords:
Food, Allergy, ImmunotherapyAbstract
Food allergy(FA) is emerging as a global social issue. It is a potentially life threatening condition with a negative impact on quality of life of patients and their families. However, the current standard approach is relegated to the strict avoidance of triggering food(s) and the use of rescue medication in the case an allergic reaction occurs.
Oral Immunotherapy (OIT) represent an effective, active treatment for FA, able to increase the amount of food that the patient can intake without reaction during treatment (i.e desensitization) and reduces the risk of potential of severe allergic reaction in the event of accidental ingestion. The key messages of the Guidelines of the European Academy of Allergy and Clinical Immunology (EAACI) suggest that OIT should be considered for children form around 4-5 years of age with symptoms suggestive of persistent IgE mediated food allergy. Caused by cow’s milk, hen’s egg or peanut.
Currently, for OIT the use of fresh food or native food is advisable. OIT represents a typical hospital treatment administered by competent personnel i.e doctors and nurses. At present time there are just fresh food or native food available for OIT. During many decades, the supportive management of food allergy consisted of avoidance of offending food and early recognition and treatment of anaphylaxis. Nowadays, looking into this matter, the time is ripe for practice of OIT in selected medical centers and under medical supervision with the goal of improving quality of life of patients and their families.
References
1. Pajno, GB., Castagnoli, R., Muraro, A., Alvaro-Lozano, M., Akdis, CA., Akdis, M., Arasi, S. (2019). Allergen Immunotherapy for IgE-Mediated Food Allergy: there is a measure in everything to a proper proportion of therapy.Pediatr Allergy Immunol. Feb 15 doi: 10.1111/pai.13042.
2. Scurlock, AM., (2018). Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy. Clin Rev Allergy Immunol. Oct;55(2):139-152. doi: 10.1007/s12016-018-8677-0.
3. Pajno, GB., Fernandez-Rivas, M., Arasi, S., Roberts, G., Akdis, CA. (2018). EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. Apr;73(4):799-815. doi: 10.1111/all.13319.
4. Arasi, S., Caminiti, L., Crisafulli, G., Pajno, GB. (2018). A general strategy for de novo immunotherapy design: the active treatment of food allergy. Expert Rev ClinImmunol. Aug;14(8):665-671. doi: 10.1080/1744666X.2018.1498784.
5. Jones, SM., Sicherer, SH., Burks, AW., Leung, DY., Lindblad, RW. (2017). Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J AllergyClinImmunol. Apr; 139(4):1242-1252.e9. doi: 10.1016/j.jaci.2016.08.017.
6. Mori, F., Cianferoni, A., Brambilla, A., Barni, S., Sarti, L., (2017). Side effects and their impact on the success of milk oral immunotherapy (OIT) in children. Int J ImmunopatholPharmacol. Jun;30(2):182-187. doi: 10.1177/0394632017697986.
7. Skripak, JM., Matsui, EC., Mudd, K., Wood, RA. (2007). The natural history of IgE mediated cow’s milk allergy J Allergy ClinImmunol. Nov;120(5):1172-7. doi: 10.1016/j.jaci.2007.08.023
8.Agache, I. (2018). EAACI guidelines on allergen immunotherapy – Out with old and in with the new.Allergy. Apr; 73 (4): 737-738. doi: 10.1111/all.13393.
9. Muraro, A., Werfel, T., Hoffmann-Sommergruber, K.,Roberts, G.,Beyer, K.,Bindslev-Jensen, C., et al. (2014). EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. Aug; 69 (8): 1008-25. doi: 10.1111/all.12429.
Arasi, S., Caminiti, L., Crisafulli, G., Panasiti, I., Barbalace, A., Passalacqua, G., Pajno, GB. (2019). The safety of oralimmunotherapy for food allergy during maintenance phase: Effect of counselling on adverse reactions.World Allergy Organ J. Jan 26;12(1):100010. doi: 10.1016/j.waojou.2018.11.008.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
